Skip to main content
Erschienen in: Rheumatology International 11/2008

01.09.2008 | Original Article

New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer

verfasst von: Hiroyuki Murota, Yorihisa Kotobuki, Noriko Umegaki, Mamori Tani, Ichiro Katayama

Erschienen in: Rheumatology International | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

It is considered that the mechanism in intractable cutaneous ulcer is deeply associated with prolongation at the inflammatory phase. Having evaluated the effects of Lipo-prostaglandin E1 (Lipo-PGE1) with indicators such as the reduction ratio of the ulcer area and the values of the inflammatory markers after dividing them into two groups of collagen diseases and non-collagen diseases and giving them Lipo-PGE1, we managed to obtain the result that Lipo-PGE1 administration could influence various inflammatory markers such as C-reactive protein (CRP), IL-6, and VEGF in addition to reduction of the ulcer region. It also suggested that Lipo-PGE1 has the effect of maintaining an appropriate balance of induction of inflammation and angiogenesis. Additionally, it revealed that Lipo-PGE1 controls the production of cytokines, which are associated with the growth of collagen diseases. From these results, it can be expected that Lipo-PGE1 will act favorably on intractable collagen diseases.
Literatur
1.
Zurück zum Zitat Yamaguchi Y, Yoshikawa K (2001) Cutaneous wound healing: an update. J Dermatol 28:521–534PubMed Yamaguchi Y, Yoshikawa K (2001) Cutaneous wound healing: an update. J Dermatol 28:521–534PubMed
2.
Zurück zum Zitat Cianfarani F, Tommasi R, Failla CM, Viviano MT, Annessi G, Papi M, Zambruno G, Odorisio T (2006) Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endtherial growth factor transcription in the ulcer bed. Br J Dermatol 154:34–41PubMedCrossRef Cianfarani F, Tommasi R, Failla CM, Viviano MT, Annessi G, Papi M, Zambruno G, Odorisio T (2006) Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endtherial growth factor transcription in the ulcer bed. Br J Dermatol 154:34–41PubMedCrossRef
3.
Zurück zum Zitat Lauer G, Sollberg S, Colo M, Flamme I, Sturzebecher J, Mann K, Krieg T, Eming SA (2000) Expression and proteolysis of vascular endtherial growth factor is increased in chronic wounds. J Invest Dermatol 115:12–18PubMedCrossRef Lauer G, Sollberg S, Colo M, Flamme I, Sturzebecher J, Mann K, Krieg T, Eming SA (2000) Expression and proteolysis of vascular endtherial growth factor is increased in chronic wounds. J Invest Dermatol 115:12–18PubMedCrossRef
4.
Zurück zum Zitat Papps PJ, Fallek SR, Gracia A, Anaki CT, Back TL, Duran WK, Hobson RW 2nd (1995) Role of leukocyte activation in patients with venous stasis ulcers. J Surg Res 59:553–559CrossRef Papps PJ, Fallek SR, Gracia A, Anaki CT, Back TL, Duran WK, Hobson RW 2nd (1995) Role of leukocyte activation in patients with venous stasis ulcers. J Surg Res 59:553–559CrossRef
5.
Zurück zum Zitat Frenkel O, Shani E, Ben-Bassat I, Brok-Simoni F, Rozenfeld-Granot G, Kajakaro G, Rechavi G, Amariglio N, Shinar E, Danon D (2002) Activated macrophages for treating skin ulceration:gene expression in human monocytes after hypo-osmotic shock. Clin Exp Immunol 128:59–66PubMedCrossRef Frenkel O, Shani E, Ben-Bassat I, Brok-Simoni F, Rozenfeld-Granot G, Kajakaro G, Rechavi G, Amariglio N, Shinar E, Danon D (2002) Activated macrophages for treating skin ulceration:gene expression in human monocytes after hypo-osmotic shock. Clin Exp Immunol 128:59–66PubMedCrossRef
6.
Zurück zum Zitat Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G (1989) Dual contorol of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 8:3773–3779PubMed Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G (1989) Dual contorol of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 8:3773–3779PubMed
7.
Zurück zum Zitat Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD (1991) A form of circulating ICAM-1 in human serum. J Immunol 147:3788–3793PubMed Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD (1991) A form of circulating ICAM-1 in human serum. J Immunol 147:3788–3793PubMed
8.
Zurück zum Zitat Hahn J, Junger M, Friedrich B, Zuder D, Steins A, Hahn M, Klyscz T (1997) Cutaneous inflammation limited to the region of the ulcer in chronic venous insufficiency. Vasa 26:277–281PubMed Hahn J, Junger M, Friedrich B, Zuder D, Steins A, Hahn M, Klyscz T (1997) Cutaneous inflammation limited to the region of the ulcer in chronic venous insufficiency. Vasa 26:277–281PubMed
9.
Zurück zum Zitat Rowe IF, Deans AC (1986) Serum C-reactive protein measurement in pyoderma gangreosom. Dermatologica 173:216–219PubMed Rowe IF, Deans AC (1986) Serum C-reactive protein measurement in pyoderma gangreosom. Dermatologica 173:216–219PubMed
10.
Zurück zum Zitat Heshmat NM, EL-Kerdanv TH (2007) Serum levels of vascular endothrial growth factor in children and adolescents with systemic lupus erythematosus. Pediatr Allergy Immunol 18:346–353PubMedCrossRef Heshmat NM, EL-Kerdanv TH (2007) Serum levels of vascular endothrial growth factor in children and adolescents with systemic lupus erythematosus. Pediatr Allergy Immunol 18:346–353PubMedCrossRef
11.
Zurück zum Zitat Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K (1998) Serum concentrations of vascular endothrial growth factor in collagen diseases. Br J Dermatol 139:1049–1051PubMedCrossRef Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K (1998) Serum concentrations of vascular endothrial growth factor in collagen diseases. Br J Dermatol 139:1049–1051PubMedCrossRef
12.
Zurück zum Zitat Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF (1994) Vascular permeability factor/endothrial growth factor (VPF/VEGF) accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341–346PubMedCrossRef Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF (1994) Vascular permeability factor/endothrial growth factor (VPF/VEGF) accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341–346PubMedCrossRef
13.
Zurück zum Zitat Murphy MA, Jovce WP, Condron C, Bouchier-Haves D (2002) A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy. Eur J Vasc Endovasc Surg 23:349–352PubMedCrossRef Murphy MA, Jovce WP, Condron C, Bouchier-Haves D (2002) A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy. Eur J Vasc Endovasc Surg 23:349–352PubMedCrossRef
14.
Zurück zum Zitat Drinkwater SL, Burnand KG, Ding R, Smith A (2003) Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers. J Vasc Surg. 38:1106–1112PubMedCrossRef Drinkwater SL, Burnand KG, Ding R, Smith A (2003) Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers. J Vasc Surg. 38:1106–1112PubMedCrossRef
15.
Zurück zum Zitat Aoki S, Imai K, Yachi A (1993) Soluble intercellular adhesion molecule-1 (ICAM-1) antigen in patients with rheumatoid arthritis. Scand J Immunol 38:485–490PubMedCrossRef Aoki S, Imai K, Yachi A (1993) Soluble intercellular adhesion molecule-1 (ICAM-1) antigen in patients with rheumatoid arthritis. Scand J Immunol 38:485–490PubMedCrossRef
16.
Zurück zum Zitat Machold KP, Kiener HP, Graninger W, Graninger WB (1993) Soluble intercellular adhesion molecule-1(ICAM-1) in patients with rheumatoid arthritis and systemic lupus erthmatosus. Clin Immunol Immunopathol 68:74–78PubMedCrossRef Machold KP, Kiener HP, Graninger W, Graninger WB (1993) Soluble intercellular adhesion molecule-1(ICAM-1) in patients with rheumatoid arthritis and systemic lupus erthmatosus. Clin Immunol Immunopathol 68:74–78PubMedCrossRef
17.
Zurück zum Zitat Cush JJ, Rothlein R, Lindslev HB, Mainolfi EA, Lipskv PE (1993) Increased levels of circulating intercellular adhesion molecute 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 36:1098–1102PubMedCrossRef Cush JJ, Rothlein R, Lindslev HB, Mainolfi EA, Lipskv PE (1993) Increased levels of circulating intercellular adhesion molecute 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 36:1098–1102PubMedCrossRef
18.
Zurück zum Zitat Sfikakis PP, Tesar J, Baraf H, Lipnick R, Klipple G, Tsokos GO (1993) Circulating intercellular adhesion molecute-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 68:88–92PubMedCrossRef Sfikakis PP, Tesar J, Baraf H, Lipnick R, Klipple G, Tsokos GO (1993) Circulating intercellular adhesion molecute-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 68:88–92PubMedCrossRef
19.
Zurück zum Zitat Kiener H, Graninger W, Machold K, Aringer M, Graninger WB (1994) Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Exp Rheumatol 12:483–487PubMed Kiener H, Graninger W, Machold K, Aringer M, Graninger WB (1994) Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Exp Rheumatol 12:483–487PubMed
20.
Zurück zum Zitat Murota H, Muroi E, Yamaoka T, Hamasaki Y, Katayama I (2006) Successful treatment with regimen of intravenous gamma globulin and cyclophosphamide for dermatomyositis accompanied by interstitial pneumonia, opportunistic infection and steroid psychosis. Allergol Int 55:199–202PubMedCrossRef Murota H, Muroi E, Yamaoka T, Hamasaki Y, Katayama I (2006) Successful treatment with regimen of intravenous gamma globulin and cyclophosphamide for dermatomyositis accompanied by interstitial pneumonia, opportunistic infection and steroid psychosis. Allergol Int 55:199–202PubMedCrossRef
21.
Zurück zum Zitat Mizushima Y, Yanagawa A, Hoshi A (1983) Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J Pharm Pharmacol 35:666–667PubMed Mizushima Y, Yanagawa A, Hoshi A (1983) Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J Pharm Pharmacol 35:666–667PubMed
22.
Zurück zum Zitat Tsutsui K, Shirasaki F, Takata M, Takehara K (1996) Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation. Dermatology 192:120–124PubMedCrossRef Tsutsui K, Shirasaki F, Takata M, Takehara K (1996) Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation. Dermatology 192:120–124PubMedCrossRef
Metadaten
Titel
New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer
verfasst von
Hiroyuki Murota
Yorihisa Kotobuki
Noriko Umegaki
Mamori Tani
Ichiro Katayama
Publikationsdatum
01.09.2008
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 11/2008
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-008-0589-5

Weitere Artikel der Ausgabe 11/2008

Rheumatology International 11/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.